Literature DB >> 28627787

Psychiatric and cognitive characteristics of individuals with Danon disease (LAMP2 gene mutation).

Maya Yardeni1, Omri Weisman1,2, Hanna Mandel3, Ronnie Weinberger1, Giovanni Quarta4, Joel Salazar-Mendiguchía5,6, Pablo Garcia-Pavia7, Maria José Lobato-Rodríguez8, Lourdes Fajardo Simon8, Freimark Dov9,10, Michael Arad9,10, Doron Gothelf1,2,10.   

Abstract

Danon disease (DD) is a rare X-linked disorder caused by loss-of-function mutations in the LAMP2 gene, which encodes lysosome-associated membrane protein. It is characterized by the triad of hypertrophic cardiomyopathy, myopathy, and intellectual disability. Whereas the molecular and pathophysiological mechanisms underlying this disorder have been previously reported and continue to be explored, the cognitive deficits and psychiatric comorbidities manifested in DD remain an understudied topic. We systematically assessed cognitive abilities and psychiatric comorbidities in 13 males and females. Most of the participants in our cohort (n = 9; 75%) had an IQ score within the normal range, while only one participant had intellectual disability. Participants' performance on the Cognitive Neuropsychiatric Battery (CNB) showed only mildly impaired cognitive abilities in most modules, except in the executive functioning test, which was low compared to healthy controls. Of note, 69% of the participants met criteria for at least one psychiatric disorder, mainly mood and anxiety disorders, occurring alone or in combination in the same patient. The results of the present study challenge earlier reports suggesting that mental retardation is a core constituent in DD. Of importance, it underscores the need to refer Danon patients to psychiatric assessment.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  Danon disease; IQ; LAMP2; Wolff-Parkinson-White syndrome; cardiomyopathy; cognition; psychiatric comorbidities

Mesh:

Substances:

Year:  2017        PMID: 28627787      PMCID: PMC5561494          DOI: 10.1002/ajmg.a.38320

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  16 in total

1.  Treatment of depression in an adolescent with cardiomyopathy and arrhythmia.

Authors:  Canan Tanidir; Ibrahim C Tanidir; Volkan Tuzcu
Journal:  Cardiol Young       Date:  2014-11-17       Impact factor: 1.093

2.  Lysosomal glycogen storage disease with normal acid maltase.

Authors:  M J Danon; S J Oh; S DiMauro; J R Manaligod; A Eastwood; S Naidu; L H Schliselfeld
Journal:  Neurology       Date:  1981-01       Impact factor: 9.910

3.  Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease).

Authors:  I Nishino; J Fu; K Tanji; T Yamada; S Shimojo; T Koori; M Mora; J E Riggs; S J Oh; Y Koga; C M Sue; A Yamamoto; N Murakami; S Shanske; E Byrne; E Bonilla; I Nonaka; S DiMauro; M Hirano
Journal:  Nature       Date:  2000-08-24       Impact factor: 49.962

4.  Neurocognitive profile in psychotic versus nonpsychotic individuals with 22q11.2 deletion syndrome.

Authors:  Ronnie Weinberger; James Yi; Monica Calkins; Yael Guri; Donna M McDonald-McGinn; Beverly S Emanuel; Elaine H Zackai; Kosha Ruparel; Miri Carmel; Elena Michaelovsky; Abraham Weizman; Ruben C Gur; Raquel E Gur; Doron Gothelf
Journal:  Eur Neuropsychopharmacol       Date:  2016-08-12       Impact factor: 4.600

5.  The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses.

Authors:  Stefan G Hofmann; Anu Asnaani; Imke J J Vonk; Alice T Sawyer; Angela Fang
Journal:  Cognit Ther Res       Date:  2012-07-31

6.  Early onset of cardiomyopathy and intellectual disability in a girl with Danon disease associated with a de novo novel mutation of the LAMP2 gene.

Authors:  Kazuma Sugie; Hiroyuki Yoshizawa; Kenji Onoue; Yoko Nakanishi; Nobuyuki Eura; Megumu Ogawa; Tomoya Nakano; Yasuhiro Sakaguchi; Yukiko K Hayashi; Toshifumi Kishimoto; Midori Shima; Yoshihiko Saito; Ichizo Nishino; Satoshi Ueno
Journal:  Neuropathology       Date:  2016-05-05       Impact factor: 1.906

7.  Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies.

Authors:  George I Papakostas; Stephen M Stahl; Alok Krishen; Cheryl A Seifert; Vivian L Tucker; Elizabeth P Goodale; Maurizio Fava
Journal:  J Clin Psychiatry       Date:  2008-08       Impact factor: 4.384

Review 8.  Clinicopathological features of genetically confirmed Danon disease.

Authors:  K Sugie; A Yamamoto; K Murayama; S J Oh; M Takahashi; M Mora; J E Riggs; J Colomer; C Iturriaga; A Meloni; C Lamperti; S Saitoh; E Byrne; S DiMauro; I Nonaka; M Hirano; I Nishino
Journal:  Neurology       Date:  2002-06-25       Impact factor: 9.910

Review 9.  Depression and health-related quality of life in people with coronary heart disease: a systematic review.

Authors:  Chris Dickens; Andrea Cherrington; Linda McGowan
Journal:  Eur J Cardiovasc Nurs       Date:  2012-03-28       Impact factor: 3.908

10.  Natural history of Danon disease.

Authors:  Dana Boucek; Jean Jirikowic; Matthew Taylor
Journal:  Genet Med       Date:  2011-06       Impact factor: 8.822

View more
  6 in total

Review 1.  Mitophagy in depression: Pathophysiology and treatment targets.

Authors:  Ashutosh Tripathi; Giselli Scaini; Tatiana Barichello; João Quevedo; Anilkumar Pillai
Journal:  Mitochondrion       Date:  2021-08-31       Impact factor: 4.160

Review 2.  Storage diseases with hypertrophic cardiomyopathy phenotype.

Authors:  Luis Ruiz-Guerrero; Roberto Barriales-Villa
Journal:  Glob Cardiol Sci Pract       Date:  2018-08-12

3.  A family with Danon disease caused by a splice site mutation in LAMP2 that generates a truncated protein.

Authors:  Nianwei Zhou; Jie Cui; Weipeng Zhao; Yingying Jiang; Wenqing Zhu; Lu Tang; Xuejie Li; Minmin Sun; Cuizhen Pan; Xianhong Shu
Journal:  Mol Genet Genomic Med       Date:  2019-02-03       Impact factor: 2.183

Review 4.  Update Review about Metabolic Myopathies.

Authors:  Josef Finsterer
Journal:  Life (Basel)       Date:  2020-04-17

5.  Case Report: A Novel LAMP2 Splice-Altering Mutation Causes Cardiac-Only Danon Disease.

Authors:  Zongzhe Li; Fei Ma; Rui Li; Zhichao Xiao; Hesong Zeng; Dao Wen Wang
Journal:  Front Cardiovasc Med       Date:  2021-11-25

6.  A case report of delayed diagnosis of danon disease: Caused by a newly recognized mutation in the lysosome-associated membrane protein-2 gene.

Authors:  Ying Zhang; Hang Ren; Shanshan Zhou
Journal:  Medicine (Baltimore)       Date:  2020-10-02       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.